CapTemY90 for Grade 2/3 NET Liver Metastases
Recruiting · Phase 2 · NCT04339036
Conditions: Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors
At a glance
- Research payments reported, 2025
- $413,927
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 70
About the trial
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Tested
- Capecitabine Oral Product (drug), Temozolomide Oral Product (drug), transarterial radioembolization (combination_product)
- Dates
- Started 2021-10-07; completion 2028-07-01
- Results posted
- Not yet
This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation from either therapy alone. A Grade 3 arm was added in 2025.
From ClinicalTrials.gov, last updated 2026-10-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sirtex Medical Inc reported $413,927 in research payments for this study in 2025 (2 payments).
Products named: Sir-Spheres Microspheres
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.